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PPARγ is a therapeutic target that has been exploited for treatment of type II diabetes mellitus (T2DM) with agonist drugs. Since
PPARγ is expressed by many hematopoietic, mesodermal and epithelial cancers, agonist drugs were tested and shown to have
both preclinical and clinical anticancer activity. While preclinical activity has been observed in many cancer types, clinical activity
has been observed only in pilot and phase II trials in liposarcoma and prostate cancer. Most studies address agonist compounds,
with substantially fewer reports on anticancer eﬀects of PPARγ antagonists. In cancer model systems, some eﬀects of PPARγ
agonists were not inhibited by PPARγ antagonists, suggesting noncanonical or PPARγ-independent mechanisms. In addition,
PPARγ antagonists, such as T0070907 and GW9662, have exhibited antiproliferative eﬀects on a broad range of hematopoietic
and epithelial cell lines, usually with greater potency than agonists. Also, additive antiproliferative eﬀects of combinations of
agonist plus antagonist drugs were observed. Finally, there are preclinical in vivo data showing that antagonist compounds can
be administered safely, with favorable metabolic eﬀects as well as antitumor eﬀects. Since PPARγ antagonists represent a new drug
class that holds promise as a broadly applicable therapeutic approach for cancer treatment, it is the subject of this review.
Copyright © 2008 Jack D. Burton et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
PPARγ is one of the three known peroxisome proliferator-
activated receptors and is a member of the nuclear receptor
(NR) superfamily. Since it has a predominantly nuclear
location, regardless of whether cognate ligands are present,
it is classiﬁed as a type II NR. It functions as a transcription
factor by heterodimerizing with the retinoid X receptor
(RXR), after which this complex binds to speciﬁc DNA
sequence elements called peroxisome proliferator response
elements (PPREs) [1]. In order to become fully active as
a transcription factor, PPARγ must be bound by ligand.
RXR can be aﬀected by binding its own cognate ligands,
usually resulting in incremental increases in transcriptional
activity. After the PPARγ/RXR heterodimer binds to PPREs
in promoter regions of target genes, coactivator proteins,
such as p300 (CBP), SRC-1, and Drip205 (or TRAP220)
family members, are recruited to this complex to modulate
gene transcription [2–4]. Diﬀerent PPARγ ligands appear to
be able to recruit diﬀerent coactivators, which may explain
diﬀerences in the biological activity between ligands [5].
The cardinal biologic activity of PPARγ is the induction
of diﬀerentiation of adipocytes, the cell type that expresses
the highest levels of PPARγ amongst normal tissues. Lower
levels of PPARγ are, however, found in other normal tissues
and cell types such as skeletal muscle, liver, breast, prostate,
colon, type 2 alveolar pneumocytes, some endothelial cells
as well as monocytes, and B-lymphocytes. There are three
PPARγ mRNA isoforms (γ1, γ2, and γ3) and two major pro-
tein species (γ1a n dγ2). The mRNA isoforms are generated
by alternate promoter usage, resulting in an additional 28
amino acids at the N-terminus of PPARγ2 compared with
PPARγ1. Most tissues express PPARγ1, whereas the PPARγ2
isoform is expressed mostly by adipocytes. The longer N-
terminal domain of PPARγ2m a ya ﬀect function, since this
isoform was shown to confer a higher level of ligand-
independent transcriptional activity, which was further
increased by physiologic concentrations of insulin [6]. High2 PPAR Research
levels of PPARγ expression by fat and its role in adipogenesis
led to the recognition that agonistic PPARγ ligands have
antidiabetic eﬀects. The chemical class of PPARγ agonists
known as thiazolidinediones (TZDs) demonstrated high-
aﬃnity binding to PPARγ [7] as well as favorable therapeutic
properties, and such drugs were eventually registered for
the treatment of type II diabetes mellitus (T2DM). Three
TZD drugs have been registered in the U.S.: rosiglitazone
(Avandia), pioglitazone (Actos), and troglitazone(Rezulin).
Subsequenttoitsmarketingandwidespreaduse,troglitazone
was associated with idiosyncratic and, in rare cases, fatal
hepatic toxicity, and, thus, was withdrawn from the market.
The former two drugs, however, have remained as safe and
eﬀective therapeutic options for the management of T2DM.
Not long after reports of the cloning of PPARγ and its
expression in normal tissues [8, 9], PPARγ expression was
observed in an array of primary cancers and derivative cell
lines. Its expression was reported initially in liposarcoma
[10], and soon thereafter in colon, breast, and prostate car-
cinomas and additional cancer types [11–14]. In addition to
theinvitroandpreclinicalinvivoanticancereﬀectsofTZDs,
pilot clinical studies using troglitazone showed antitumor
activity in patients with liposarcoma and prostate cancer
[15, 16]. Compounds from other chemical classes were also
shown to bind PPARγ and to have antiproliferative eﬀects in
cancer models, such as the naturally occurring eicosanoid,
15-deoxy-Δ12,14-prostaglandin J2(15-d-PGJ2), the N-aryl
tyrosine derivative, GW1929 [17], and the triterpenoid, 2-
cyano-3,12-dioxooleana-1,9-diene-28-oic acid, CDDO [18].
While compounds that exhibit PPARγ agonist activity, such
as TZDs, have PPARγ-dependent antiproliferative eﬀects,
they have also been shown to have antiproliferative eﬀects in
cell types that are genetically PPARγ-null [19]. Also, uncer-
tainty about mechanisms of anticancer eﬀects of PPARγ
ligands has resulted from variability in the classiﬁcation
of some compounds (e.g., bisphenol A diglycidyl ether
[BADGE], which has been shown to have both agonist and
antagonist activities) [20, 21].
2. EFFECTS OF PPARγ ANTAGONIST COMPOUNDS
IN EPITHELIAL CANCER MODEL SYSTEMS: CELL
GROWTH AND APOPTOSIS
The initial report of Fehlberg et al. [22] showed an
inhibitory eﬀect of this class of agents on a colon cancer
and a lymphoma cell line using the compound, BADGE,
w h i c ha sn o t e dh a sb e e nc l a s s i ﬁ e da sb o t ha na g o n i s ta n d
antagonist. This initial study did not examine eﬀects on
proliferation, but showed that apoptotic eﬀects, such as
increases in annexin-V binding and reductions in DNA
content as assessed by propidium iodide staining, required
50–100μM concentrations of BADGE, which would tend to
increase oﬀ-target eﬀects. Subsequently, Seargent et al. [23]
showed that a higher aﬃnity, selective PPARγ antagonist,
GW9662, had direct antiproliferative eﬀects on three breast
cancer cell lines of diﬀering phenotypes (ER+, ER−,a n d
p53-null). This antagonist compound was somewhat more
potent in its eﬀects than an agonist (rosiglitazone). In this
report, the role of PPARγ in mediating growth inhibition
was addressed, but not fully elucidated. All three cell lines
expressed it and the predicted, canonical PPARγ-related
transactivation eﬀects were demonstrated, with the agonist
inducing transactivation and the antagonist suppressing
it, thus excluding PPARγ-mediated transactivation as the
mechanism of this eﬀect. There are data, however, that
suggest that antagonist-type compounds may also act via
otherPPARγ-dependentpathways.Leaetal.reportedsimilar
results using a range of agonist and antagonist compounds
on both murine and human cell lines [24]. Schaefer et
al. showed that the antiproliferative eﬀect of the PPARγ
antagonist, T0070907, on hepatocellular carcinoma cell
lines was attenuated by knockdown of PPARγ by siRNA
[25]. These data are consistent with a PPARγ-mediated
transrepression mechanism, which has been demonstrated
with respect to anti-inﬂammatory eﬀects of PPARγ ligands
mediated by the NF-κB signaling pathway. Pascual et al.
showed similar eﬀects of a pure agonist (rosiglitazone) and
a mixed agonist/antagonist (GW0072) on the repression
o faN F - κB-regulated gene, iNOS, suggesting that pure
antagonists may also be capable of mediating this eﬀect [26].
There are also data that PPARγ ligands (both agonist
and antagonist) exert PPARγ-independent eﬀects suggest-
ing other cellular targets of these compounds. This was
demonstrated clearly by Palakurthi et al., who demonstrated
in vitro and in vivo growth inhibition of two agonist
compounds, troglitazone and ciglitazone, in experiments
utilizing PPARγ−/− and PPARγ+/+ embryonic stem cell lines
(ES), both of which exhibited very similar sensitivity to these
compounds [19]. This eﬀect was shown to be mediated in
part by the inhibition of the initiation of protein translation,
since these TZD compounds increased the phosphorylation
and consequent inactivation of elongation-initiation factor 2
(eIF2) both in cells that expressed and were null for PPARγ.
The eﬀect of antagonist compounds on this pathway has not
been reported. As noted, BADGE had similar proapoptotic
eﬀects in a colon cancer line expressing PPARγ and a T-
lymphoma line that showed no detectable expression of it
(by immunoblotting and RT-PCR) of this target [22]. But,
given the variable classiﬁcation of this compound as both an
antagonist and agonist, the mechanism underlying this eﬀect
and its attribution are unclear.
3. OTHER EFFECTS OF PPARγ
ANTAGONIST COMPOUNDS
PPARγ antagonist compounds have also been shown to
aﬀect cell shape, adhesion, and invasiveness of cancer cell
lines. Masuda et al. evaluated the eﬀects of the PPARγ
antagonists, BADGE, GW9662 and T0070907, on four
squamous carcinoma cell lines derived from tumors of the
oral cavity. Antiproliferative eﬀects were shown for the three
antagonists,butnotfortheagonist,pioglitazone[27].Eﬀects
of these agents on adhesion and anoikis were also evaluated.
Antagonists were found to inhibit adhesion and induce
cell death related to loss of adhesion (known as anoikis)
under normal tissue culture conditions on untreated plastic
dishes. T0070907 induced similar inhibition of adhesion to
ﬁbronectin-coated plates, and this was signiﬁcantly reversedJack D. Burton et al. 3
by coincubation of cells with this antagonist and the agonist,
pioglitazone, suggesting a PPARγ-dependent eﬀect. Since
adhesionanddetachmentarerelatedtocytoskeletalstructure
and function, this was assessed by ﬂuorescent staining of
F-actin. Using confocal microscopy, T0070907 was shown
to cause dose-dependent disruption of F-actin, associated
with rounding of the cells. Additional experiments showed
inhibition of FAK and MEK-ERK signaling pathways, as well
as decreased expression of integrin α5 and CD151, both
of which are adhesion proteins that have been implicated
in cancer cell invasion and metastasis. Schaefer et al.
showed similar eﬀects of PPARγ antagonists on hepatocel-
lular carcinoma cell lines including inhibition of adhesion,
induction of anoikis, and inhibition of phosphorylation and
activation of FAK [25]. These eﬀects were shown to be
dependent on the degree of PPARγ inhibition, and could
be mediated by the antagonist or knockdown of PPARγ via
speciﬁc, cognate siRNA. T0070907 was also shown to have
substantially greater growth inhibitory eﬀects on the HepG2
line compared with the agonist drugs, troglitazone, and
rosiglitazone. Takahashi et al. demonstrated anti-invasive
and growth inhibitory eﬀects of the antagonists, GW9662
and T0070907, on esophageal cancer cell lines. The anti-
invasive eﬀects were observed at levels substantially lower
than those required for growth inhibition [28]. In summary,
all of these studies addressing anticancer eﬀects of PPARγ
antagonist compounds have show eﬀects on cell growth,
adhesion, and invasion in multiple epithelial cancer models.
Some of these eﬀects are PPARγ-dependent, but the
potential role of other targets is suggested by the similar
eﬀects of BADGE on a PPARγ+ colon cancer line and a
PPARγ-negative T-lymphoma line. Also, the substantially
diﬀerent concentrations of PPARγ antagonists needed to
induce anti-invasive eﬀects versus growth inhibition in
esophageal cancer lines suggest diﬀerent mechanisms with
diﬀering degrees of PPARγ dependence or lack of involve-
ment of the PPARγ-signaling pathway for some eﬀects.
AP P A R γ-independent eﬀect of antagonists on colorectal
cancer cell lines and in an in vivo tumor xenograft derived
from one of the lines was shown in a more recent report by
Schaefer et al. [29]. A decrease in tubulin levels was observed
that was independent of PPARγ,P P A R δ,a n dp r o t e a s o m e
function. This downregulation of tubulins α and β may
explain the antimigratory, anti-invasive, and antimetastatic
eﬀects that were observed. Thus, in summary, PPARγ
antagonist compounds with varying chemical structures
(though GW9662 and T0070907 are similar) have several
signiﬁcant anticancer eﬀects in vitro and in vivo in epithelial
cancer model systems including breast, colon, aerodigestive
squamous cell, and hepatocellular.
4. EFFECTS OF PPARγ ANTAGONISTS IN
HEMATOPOIETIC CANCER MODEL SYSTEMS
Studies were conducted in our lab to assess the eﬀects
of PPARγ antagonists on hematopoietic cell lines. Initial
screening showed that several myeloma (MM) cell lines had
the greatest sensitivity to the antiproliferative eﬀects of the
antagonists, GW9662 and T0070907. Thus multiple MM
lines were tested, including one that is IL-6-dependent, for
sensitivity to these compounds as well as to the agonist,
pioglitazone. MM lines as well as non-Hodgkin lymphoma
(NHL) lines showed signiﬁcantly greater sensitivity to
the growth inhibitory eﬀects of the two antagonist drugs
compared with the agonist [30]. As a group, the MM
lines were more sensitive than the other groups of cancer
cell lines to the antiproliferative eﬀects of the antagonists,
particularly T0070907. Other goals were to directly compare
the sensitivity of previously tested epithelial cancer types
(breast and colon) to hematopoietic lines (MM and NHL)
as well as to evaluate a chemoresistant epithelial cancer
type (renal cell). These experiments showed that in all the
epithelial and hematopoietic cell lines tested, the antagonists
were signiﬁcantly more potent in their growth inhibitory
eﬀects compared with the agonist drug.
The IC50 values for the panel of 16 cell lines tested in
these studies are shown in Table 1. For each of the cell lines
in the panel, signiﬁcant diﬀerences in the IC50 values of the
antagonist compounds and the agonist drug, pioglitazone,
were observed (P values ranging from <.04 to <.001, with 12
of 16 lines at <.001). While the MM lines showed the greatest
sensitivity to the antagonists, similar degrees of sensitivity to
the antagonists were also seen in the subset of breast cancer
lines, which included two lines that are estrogen receptor-
negative.Thoughnotquiteassensitiveasasubset,signiﬁcant
diﬀerences between the antagonists and the agonist were also
observed in the renal cell lines, which are among the most
chemoresistant epithelial lines. The diﬀerential sensitivities
within and across cell lines did not appear to be related to
the levels of PPARγ expression. Also, neither the agonist nor
the antagonist induced signiﬁcant upregulation of PPARγ
as has been reported in some studies with PPARγ ligands.
Consistent with prior reports, combinations of the agonist
and with each of the antagonists did not result in attenuation
of growth inhibitory eﬀects. In fact, schedule-dependent
increases in growth inhibition were observed, particularly
when the antagonists were added to cells 24 hours prior to
the agonist. Aspects of the mechanisms of cytotoxicity of the
antagonists and agonists were also compared. It was shown
that both classes of PPARγ ligand-induced apoptotic eﬀects,
but this eﬀect was found to be caspase-independent for the
agonist, pioglitazone [30].
Another question that was addressed was the impact of
IL-6 on the responses of the MM lines to PPARγ antagonists,
since this is a cytokine that plays a central role in the
pathogenesis and progression of MM, as well as other
cancer types. For these studies, 4 of the 5 MM lines that
were utilized were IL-6-independent in order to follow up
on a previous report of Wang et al. that analyzed the
responses of three MM lines to the PPARγ agonists, 15-
d-PGJ2 and troglitazone. This report showed that growth
inhibition and certain downstream signaling events were
PPARγ-dependent, and also that two IL-6-dependent MM
lines expressed PPARγ while an IL-6-independent line did
not [31]. Also, GW9662 was reported to block the eﬀects of
the agonists, and had no antiproliferative activity on its own.
We utilized ﬁve diﬀerent MM lines, of which four are IL-6
independent (CAG, KMS12-BM, KMS12-PE, and OPM-6)4 PPAR Research
Table 1: Mean IC50 values (μM) for the PPARγ ligands.
Cell lines Pioglitazone T0070907 GW9662
Colon
Moser# 26.5 ±2.61 5 .9 ±1.02 0 .1 ±0.3
HT29§ 53.0 ±4.71 1 .2 ±0.01 4 .1 ±0.5
LS174T# 38.7 ±7.47 .8 ±1.99 .5 ±0.5
HCT-15§ 53.1 ±2.51 3 .0 ±0.51 9 .0 ±0.8
RCC
A498# 38.9 ±4.92 4 .3 ±0.72 9 .1 ±0.3
ClearCa-2§ 56.4 ±3.12 0 .8 ±1.92 1 .5 ±0.7
Breast
ZR75-30§ 77.9 ±7.03 .9 ±0.31 0 .6 ±0.9
MCF7§ 54.8 ±3.91 0 .2 ±1.91 6 .6 ±2.4
MDA-MB-231§ 78.7 ±3.52 0 .1 ±1.12 6 .8 ±1.0
MM
CAG∗ 62.4 ±9.91 2 .2 ±1.21 3 .8 ±0.1
KMS12-BM§ 33.2 ±5.13 .2 ±0.61 1 .8 ±1.6
KMS12-PE§ 56.4 ±1.54 .3 ±0.39 .5 ±0.9
OPM6§ 48.9 ±1.84 .1 ±0.31 1 .5 ±0.1
U266B1§ 56.6 ±1.39 .9 ±0.22 9 .7 ±1.5
NHL
Ramos§ 66.5 ±7.41 2 .7 ±0.71 5 .1 ±0.1
SU-DHL6§ 53.1 ±1.41 1 .8 ±0.41 4 .8 ±0.3
Mean IC50 values from replicate experiments with this panel of cells for
each of the three PPARγ ligands are shown above, expressed in μM ± SEM.
Cell lines are grouped according to cancer type. IC50 values from each cell
line were compared by single factor ANOVA analysis, with all lines showing
signiﬁcant diﬀerences as indicated: §P<. 0001; ∗P<. 005; #P<. 04.
as well as a ﬁfth that is dependent on an IL-6 autocrine loop
(U266B1). In contrast to the prior report cited above, of the
lines analyzed, CAG expressed PPARγ, while the autocrine
IL-6-dependent line, U266B1, did not express PPARγ by
immunoblotting. Also, three of the four of IL-6-independent
MMlinesweremoresensitivetothegrowthinhibitoryeﬀects
of both of the two PPARγ antagonist compounds compared
with the IL-6-dependent line, U266B1 (see Table 1).
In MM cell lines, which are more often IL-6 dependent
compared with other B cell lines, the strict dependence on
exogenous IL-6 is indicative of ongoing requirement for this
signaling pathway, which in pathophysiologic states, such
as MM, usually depends on production of this cytokine by
stromalcells.InMM,clinicallymoreaggressiveortreatment-
resistant disease is associated with production of IL-6 by the
myeloma cell themselves as opposed to the bone marrow
stroma [32]. MM lines show a spectrum of IL-6 dependence,
with some being dependent on exogenous IL-6, others being
dependent on its autocrine production, and yet others being
IL-6-independent for their growth. Even those MM lines
that are not strictly dependent on IL-6 for their growth
(exogenous or autocrine) can still be aﬀected by the addition
of exogenous IL-6 [33] (also shown in one of the lines
tested, OPM-6, [34]). Addition of IL-6 to such MM lines
has been shown to induce either incremental stimulation of
proliferationorinductionofresistancetovariousagentssuch
as dexamethasone, standard chemotherapy drugs such as
melphalanandotheragents.ThustheinteractionofIL-6and
PPARγ antagonist compounds were examined in two MM
lines (KMS12-PE and OPM-6). MTT assays were performed
in the presence and absence of exogenous IL-6 (5 ng/mL).
For both of these MM lines, addition of IL-6 did not induce
resistance, but instead appeared to increase the sensitivity of
these lines to T0070907, with a similar trend observed with
GW9662 [30].
5. DOSE-RESPONSE EFFECTS OF
PPARγ ANTAGONIST COMPOUNDS AND
INTERACTION WITH OTHER AGENTS
The PPARγ antagonist compounds, GW9662 and T0070907,
diﬀer in their antiproliferative dose-response eﬀects com-
pared with the agonist as well as other agents. Not only
are the corresponding IC50 values for the antagonists
signiﬁcantly lower than the agonist, pioglitazone, but a
greater degree of growth inhibition (85–97% versus 50–
80%) was observed with the former compounds. Also, of
note was that the maximal eﬀects of these agents were
seen at concentrations that were only 2- to 3-fold greater
than the IC50 across the entire panel of cell lines tested
that included cell lines with relative and very high levels
of chemoresistance (colon and renal cell, resp.). The dose-
response curves were much steeper with the antagonist
compounds compared to the agonist, pioglitazone, and
also much steeper than what is observed with most other
agents, including standard chemotherapy drugs and other
agents (see Figure 2). This dose-response relationship sug-
gests either a positive cooperative eﬀect, potentially via
increased, cooperative recruitment of corepresssors, thereby
increasing transrepression. The alternate possibility is that
diﬀerent targets are being engaged with gradually increasing
concentrations, which together exhibit additive or supra-
additive interactions.
Since MM lines as a group were the most sensitive of
the cell lines we tested, interaction with other novel agents
for therapy of MM were evaluated. One such agent is anti-
CD74 monoclonal antibody (mAb). CD74 was shown to be
strongly expressed by the malignant plasma cells in the vast
majority of clinical MM specimens as well as the majority
of MM lines [35]. It was also shown that this mAb in
unlabeled (cold) form exhibited in vitro growth inhibitory
eﬀects on both NHL and MM lines [36]. The anti-CD74
mAb used in these studies, LL1, also showed signiﬁcant
therapeutic eﬀects in two preclinical murine NHL xenograft
models. In preliminary in vitro studies, the humanized anti-
CD74 mAb was combined with T0070907 in two MM lines.
These studies also evaluated a sixth MM line (KMS11),
which is IL-6 independent, expresses CD74 and is useful as
a murine MM xenograft model. This line showed similar
sensitivity to T0070907 as the other IL-6-independent lines,
with an (unpublished observations, J Burton). Another IL-
6-independent MM line that was used in initial studies,
KMS12-PE, was also used to evaluate interactions between
T0070907 and the hLL1 mAb. While KMS11 line showed
































Figure 1: The chemical structures of four PPARγ antagonists: (1)
GW9662, (2) T0070907, (3) SR-202, and (4) BADGE.
of 50–70%), the KMS12-PE line was resistant to single-
agent hLL1 (<10% inhibition). However, in combination
withT0070907,therewasasizableshifttotheleftofthedose-
response curve, as is shown in one representative experiment
in Figure 2. Current data indicate that the IC50 value
d e c r e a s e sb yf r o mam e a nv a l u eo f∼4.1μM for T0070907
alone versus ∼3.0μM with T0070907 in combination with
hLL1,suggestiveofasupra-additive eﬀect(25–30% observed
versus <8% expected based eﬀect of hLL1 alone). This is
a promising initial preclinical lead given that hLL1 is now
being evaluated in several phase I/II clinical trials in B-cell
cancers such as NHL and MM, and appears to be safe and
well tolerated.
6. OVERVIEW OF MECHANISMS OF ACTION OF PPARγ
AGONIST AND ANTAGONIST COMPOUNDS
The studies reviewed above have shown that the eﬀects
of PPARγ ligands are mediated by various mechanisms.
Some studies show or suggest canonical PPARγ-mediated
eﬀects (i.e., via transactivation), as exempliﬁed by early
in vitro studies with agonist compounds that showed fat
accumulation, a major PPARγ-mediated eﬀect, in both
breast cancer and liposarcoma cell lines [10, 12]. This
was also demonstrated in liposarcoma patients in whom
increased fat content within tumors was demonstrated by
serialCTscanningbeforeandaftertreatmentwithanagonist
drug [10]. The studies of Wang et al. showed that the





























Figure 2: Dose-response curves for the MM line, KMS12-PE, to
T0070907, both in the presence and absence of the hLL1 mAb.
Square symbols represent the dose-response curve in the presence
of hLL1, and diamond symbols represent the curve in the absence
of LL1. The ordinate shows percent growth inhibition values and
the abscissa the concentration of T0070907 in micromolar.
MM lines was seen only in lines expressing PPARγ and
that these eﬀects were reversed by cotreatment with an
antagonist compound [31]. In contrast, completely PPARγ-
independent eﬀects were demonstrated for both agonist
and antagonist compounds in reports from Palakurthi et
al. [19]a n dS c h a e f e re ta l .[ 29]. This was clearly shown
for the agonist compounds, troglitazone and ciglitazone,
which showed similar antiproliferative eﬀects in PPARγ-wild
type and PPARγ-null (knockout) embryonic stem cell lines,
both in vitro and in vivo [19]. PPARγ-independent growth
inhibitory and antimetastatic eﬀects of several antagonist
compounds were shown in both in vitro and in vivo studies
using three colon carcinoma cell lines. These eﬀects were
associated with reductions in tubulin levels and were also
shown to be independent of PPARδ and proteasome func-
tion. The PPARγ-independent eﬀect of agonist compounds
was shown to be associated with inhibitory eﬀects on the
protein translation pathway. The mechanism of PPARγ-
independent eﬀects of antagonist compounds on tubulin
levels has not been elucidated.
ThemechanismofPPARγ-mediatedtransrepressionmay
explain some of the eﬀects of antagonist compounds. This
was suggested by the attenuation of the eﬀects of antagonist
compounds by PPARγ knockdown by siRNA in hepatocel-
lular carcinoma cell lines [25]. Also, the observation that
combinations of PPARγ agonist and antagonist compounds
result in additive antiproliferative eﬀects in various cancer
cell lines [24, 30] is consistent with this mechanism. This
mechanism is plausible, as it has been shown to inhibit the
NF-κB signaling pathway, which is central to inﬂammation
and to the proliferation and survival of multiple cancer
types including hepatocellular and colon carcinomas as well
as multiple myeloma. The potential role of this and other
mechanisms remain to be determined.6 PPAR Research
7. SUMMARY OF PRECLINICAL STUDIES OF
PPARγ ANTAGONIST COMPOUNDS AND THEIR
CLINICAL POTENTIAL
The studies reviewed above have shown that PPARγ antag-
onists have in vitro and preclinical in vivo anticancer eﬀects
that are as broad and potent as agonist compounds. These
eﬀects have been demonstrated in a wide range of epithelial
cancer cell lines as well as hematopoietic cancer cell lines.
Exploration of the underlying mechanisms of action for
antagonist compounds has shown either involvement of
PPARγ or a PPARγ-independent eﬀect. One study suggested
the involvement of the canonical transactivation mechanism
in that antagonist eﬀects were antagonized by coincubation
with an agonist compound, pioglitazone [27]. In another
study, where knockdown of PPARγ aﬀected responses to
antagonist compounds, the eﬀectwas not consistent with the
canonical transactivation mechanism, but may be consistent
with a transrepressive mechanism [25]. Another study
showed that anticancer eﬀects were associated with reduc-
tions in tubulin levels (a validated cancer-related target), but
this was not mediated by PPARγ,P P A R δ, or the proteasome
[29].
While there have been numerous preclinical in vivo
s t u d i e si nc a n c e rm o d e l sw i t hP P A R γ agonists, there have
beenrelativelyfewwithantagonistcompounds.Alsoagonists
have been tested clinically. Some studies with antagonists
have been conducted in noncancer models at low doses
(≤1mg/kg), which were not toxic and biologically active [37,
38]. A chemically distinct, but selective PPARγ antagonist,
SR-202, has been synthesized and evaluated in preclinical
models (Figure 1). It was given at a dose of 400mg/kg for
periods of up to 10 weeks with favorable metabolic eﬀects
such protection against diet-induced hyperinsulinemia and
reduction in hyperinsulinemia and hyperglycemia in genet-
ically predisposed (ob/ob) mice [39]. In pilot studies, we
have administered moderate doses of GW9662 (15mg/kg)
and T0070907 (7.5 mg/kg) daily for 3 weeks by the
intraperitoneal route to immunodeﬁcient mice. These doses
and schedules were well tolerated and resulted in no signs
of toxicity (unpublished observations). These data indicate
that the doses of these antagonists that may be suﬃcient
for anticancer therapy are well tolerated, paving the way for
further development of these agents for treatment of cancer.
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